PE20221446A1 - Nuevas formulaciones de comprimido de fosfomicina - Google Patents
Nuevas formulaciones de comprimido de fosfomicinaInfo
- Publication number
- PE20221446A1 PE20221446A1 PE2022000222A PE2022000222A PE20221446A1 PE 20221446 A1 PE20221446 A1 PE 20221446A1 PE 2022000222 A PE2022000222 A PE 2022000222A PE 2022000222 A PE2022000222 A PE 2022000222A PE 20221446 A1 PE20221446 A1 PE 20221446A1
- Authority
- PE
- Peru
- Prior art keywords
- tablet
- composition
- anhydrous
- fosfomicin
- new formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Referido a una composicion farmaceutica oral en forma de comprimido que comprende: fosfomicina trometamol, hidrogenofosfato de calcio anhidro, celulosa microcristalina anhidra, opcionalmente un lubricante y otros excipientes. En donde dicha composicion comprende: desde el 80% hasta el 95% p/p de fosfomicina trometamol, desde 5% hasta 20% p/p de una combinacion de hidrogenofosfato de calcio anhidro y celulosa microcristalina anhidra, opcionalmente, desde 0,1 % hasta 3% p/p de lubricante; y otros excipientes farmaceuticamente aceptables en una cantidad suficiente para completar el 100% del peso total de la composicion. Tambien se refiere a un metodo para fabricar la composicion del comprimido y su uso como medicamento veterinario.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382104 | 2021-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221446A1 true PE20221446A1 (es) | 2022-09-21 |
Family
ID=74732835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000222A PE20221446A1 (es) | 2021-02-10 | 2022-02-09 | Nuevas formulaciones de comprimido de fosfomicina |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11833250B2 (es) |
| EP (1) | EP4043006B1 (es) |
| AR (1) | AR124833A1 (es) |
| BR (1) | BR102022002475A2 (es) |
| CA (1) | CA3147662A1 (es) |
| CO (1) | CO2022001244A1 (es) |
| CU (1) | CU20220009A7 (es) |
| ES (1) | ES2970581T3 (es) |
| MX (1) | MX2022001746A (es) |
| PE (1) | PE20221446A1 (es) |
| TW (1) | TW202245740A (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20021725A1 (it) | 2002-08-01 | 2002-10-31 | Zambon Spa | Composizioni farmaceutiche ad attivita' antibiotica. |
| ES2244333B1 (es) | 2004-05-18 | 2006-08-01 | Simbec Iberica, Sl | Preparado farmaceutico oral de fosfomicina estable y apto para diabeticos. |
| TW201129386A (en) | 2009-11-05 | 2011-09-01 | Fmc Corp | Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients |
| ES2385158B1 (es) | 2010-12-24 | 2013-05-28 | Arafarma Group, S.A. | Composición farmacéutica de fosfomicina |
| US8604078B2 (en) | 2011-04-06 | 2013-12-10 | Carlos Picornell Darder | Fosfomycin pharmaceutical composition |
-
2022
- 2022-02-03 CA CA3147662A patent/CA3147662A1/en active Pending
- 2022-02-04 CU CU2022000009A patent/CU20220009A7/es unknown
- 2022-02-08 AR ARP220100248A patent/AR124833A1/es unknown
- 2022-02-08 CO CONC2022/0001244A patent/CO2022001244A1/es unknown
- 2022-02-09 BR BR102022002475-8A patent/BR102022002475A2/pt unknown
- 2022-02-09 US US17/668,146 patent/US11833250B2/en active Active
- 2022-02-09 PE PE2022000222A patent/PE20221446A1/es unknown
- 2022-02-09 MX MX2022001746A patent/MX2022001746A/es unknown
- 2022-02-10 ES ES22156013T patent/ES2970581T3/es active Active
- 2022-02-10 EP EP22156013.9A patent/EP4043006B1/en active Active
- 2022-02-10 TW TW111104960A patent/TW202245740A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3147662A1 (en) | 2022-08-10 |
| CU20220009A7 (es) | 2023-09-07 |
| BR102022002475A2 (pt) | 2022-08-23 |
| ES2970581T3 (es) | 2024-05-29 |
| EP4043006A1 (en) | 2022-08-17 |
| MX2022001746A (es) | 2022-08-11 |
| CO2022001244A1 (es) | 2023-02-16 |
| EP4043006B1 (en) | 2023-12-06 |
| AR124833A1 (es) | 2023-05-10 |
| EP4043006C0 (en) | 2023-12-06 |
| US11833250B2 (en) | 2023-12-05 |
| TW202245740A (zh) | 2022-12-01 |
| US20220387329A1 (en) | 2022-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019000209A1 (es) | Formulación novedosa administrable por la vía oral. | |
| CO6400186A2 (es) | Tabletas de acetato de ulipristal | |
| CY1116695T1 (el) | Συνθεση περιεχοντας υπερ-μικρονοποιημενο παλμιτοϋλ-αιθανολαμιδιο | |
| UY30537A1 (es) | Formulaciones de flibanserina y metodo para fabricarlas | |
| AR069312A1 (es) | Composicion farmaceutica que comprende beta oxihidroxido de hierro en alta carga en forma adecuada para administarcion oral y que contiene al menos un hidrato de carbono y/o acido humico y su uso en el tratamiento de pacientes con hiperfosfatemia y con insuficiencia renal cronica , y procedimento pa | |
| AR066420A1 (es) | Composicion farmaceutica suministrable oronasofaringeamente para la prevencion alivio / y o tratamiento de trastornos de miembros inquietos. uso. | |
| SG158870A1 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
| PE20140960A1 (es) | Formulaciones que comprenden un inhibidor de dpp4 | |
| CL2016001411A1 (es) | Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina. | |
| AR107391A1 (es) | Formulaciones / composiciones que comprenden un inhibidor de btk | |
| AR062167A1 (es) | Sistema de administracion gastrorretentivo | |
| AR084102A1 (es) | Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de la n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, su uso para preparar un medicamento util para tratar el cancer en un ser humano y procedimiento para preparar dichos comprimidos | |
| AR061790A1 (es) | Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento | |
| AR095159A2 (es) | Una composición farmacéutica en forma de cápsula para administración oral | |
| PH12021550218A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| AR065816A1 (es) | Regimen anticonceptivo oral | |
| PE20221446A1 (es) | Nuevas formulaciones de comprimido de fosfomicina | |
| PE20142460A1 (es) | Composiciones farmaceuticas orales estables de liberacion inmediata que contienen prasugrel | |
| AR093252A1 (es) | Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla | |
| RS54721B1 (en) | PHARMACEUTICAL AEROSOL FORMOTEROL FORMULATION AND BECLOMETHASONE DIPROPIONATE | |
| CL2022003426A1 (es) | Composición farmacéutica acuosa de levilimab y su uso | |
| MX370184B (es) | Composición farmacéutica que comprende fingolimod. | |
| MY191983A (en) | Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same | |
| PE20230105A1 (es) | Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol | |
| PL422140A1 (pl) | Zastosowanie totarolu i kompozycja farmaceutyczna zawierająca totarol |